Skip to main content

Generex Biotechnology Announces Call-in Details and Agenda for Shareholder Conference Call on Friday February 5, 2021 at 9:00 AM

Written by Customer Service on . Posted in Public Companies.

The access information for the investor conference call is as follows:
Domestic US/Canada – 1-(866) 342-8588
Direct Toll / International – 1-(203) 518-9865
Program Title: Generex Biotechnology Conference Call
Conference ID – 61174AgendaUpdate on Ii-Key-SARS-CoV-2 vaccine programChina Licensing & Research Agreement advances with $100,000
payment guarantee and $1 million advance on development fundingLicensing opportunity for COVID-19 therapeutic antibodies
MIRAMAR, Fla., Feb. 03, 2021 (GLOBE NEWSWIRE) — Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced the call-in information and an updated agenda for the shareholder conference call on Friday February 5th at 9:00 am.During the call, Generex President & CEO Joe Moscato will discuss the agenda as well as new developments with the COVID-19 vaccine program.Mr. Moscato said, “We continue to make significant progress toward the clinical development of our Ii-Key-SARS-CoV-2 vaccine with the completion of our ex-vivo study of the immune response elicited by the Ii-Key epitopes selected for the final vaccine formulation. We await results of a mouse immunogenicity study requested by FDA to demonstrate the ability of the Ii-Key-SARS-CoV-2 vaccine to elicit a neutralizing antibody response and the T cell activation to generate a long-term memory immune response, thereby demonstrating the potential for a Complete Vaccine™ against COVID-19. We are using this transgenic mouse model that is genetically modified with part of the human immune system called the Human Leukocyte Antigen (HLA) to study T cell activation in an animal model of the human immune system. We have initiated the GMP production of the Ii-Key vaccine with our long-time GMP partner and contracted with a major manufacturer to fill and finish the final vaccine product in preparation for impending human clinical trials. Additionally, I will discuss our China partnership and our plans for technology transfer and vaccine development in China. Lastly, I hope to have additional information to share about ongoing discussions to license therapeutic monoclonal antibodies for the treatment of COVID-19 disease. I look forward to sharing details with shareholders on Friday.”About Generex Biotechnology Corp.
Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient-centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.About NuGenerex Immuno-Oncology
NuGenerex Immuno-Oncology, a subsidiary of Generex Biotechnology, is a clinical stage oncology company developing immunotherapeutic peptide vaccines for cancer and infectious disease based on the CD4 T-Cell activation platform, Ii-Key. NuGenerex Immuno-Oncology (NGIO) has been spun out of Generex as a separate public company to advance the platform Ii-Key technology, particularly in combination with the immune checkpoint inhibitors for the treatment of cancer. NGIO is currently engaged in a Phase II clinical trial of its lead cancer immunotherapeutic vaccine AE37 in combination with pembrolizumab (Merck’s Keytruda®) for the treatment of triple negative breast cancer. The company has also turned its Ii-Key technology on infectious disease, responding to the coronavirus pandemic with a SARS-CoV-2 vaccine development program.Cautionary Note Regarding Forward-Looking StatementsJoseph Moscato
646-599-6222Todd Falls
1-800-391-6755 Extension 222
investor@generex.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.